Skip to main content

Advertisement

Table 2 The relationship of expression levels of SOX21 and SOX21-AS1 with clinicopathologic data of OSCC patients

From: Aberrant DNA hypermethylation-silenced SOX21-AS1 gene expression and its clinical importance in oral cancer

Variables SOX21 (n = 86) SOX21-AS1 (n = 86)
Low expression High expression P value Low expression High expression P value
Number (%) Number (%) Number (%) Number (%)
Sex
 Female 5 (55.6) 4 (44.4) 1.000a 2 (22.2) 7 (77.8) 0.712a
 Male 38 (49.4) 39 (50.6) 27 (35.1) 50 (64.9)
Age
 ≤50 12 (54.5) 10 (45.5) 0.621b 8 (36.4) 14 (63.6) 0.761b
 >50 31 (48.4) 33 (51.6) 21 (32.8) 43 (67.2)
Cancer location
 Buccal and other oral mucosal sites 36 (54.5) 30 (45.5) 0.126b 25 (37.9) 41 (62.1) 0.138b
 Tongue 7 (35.0) 13 (65.0)   4 (20.0) 16 (80.0)
Cell differentiation
 Well 5 (41.7) 7 (58.3) 0.534b 4 (33.3) 8 (66.7) 1.000a
 Moderate, poor 38 (51.4) 36 (48.6) 25 (33.8) 49 (66.2)
AJCC pathological stage
 I 6 (37.5) 10 (62.5) 0.268b 2 (12.5) 14 (87.5) 0.047 b
 II, III, IV 37 (52.9) 33 (47.1) 27 (38.6) 43 (61.4)
T classification
 T1 6 (35.3) 11 (64.7) 0.176b 2 (11.8) 15 (88.2) 0.033 b
 T2, T3, T4 37 (53.6) 32 (46.4) 27 (39.1) 42 (60.9)
N classification
 N0 32 (50.0) 32 (50.0) 1.000b 20 (31.2) 44 (68.8) 0.683b
 N1, N2 11 (50.0) 11 (50.0) 9 (40.9) 13 (59.1)
  1. The italic indicated p value <0.05
  2. a P value was estimated by Fisher’s exact test
  3. b P value was estimated by chi-square test